233 related articles for article (PubMed ID: 22236410)
1. Glucagon-like peptide-1 agonists.
Padwal R
BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
[No Abstract] [Full Text] [Related]
2. GLP-1R agonists are not a quick fix for weight loss.
Iverson KA
BMJ; 2012 Feb; 344():e1455; author reply e1459. PubMed ID: 22374905
[No Abstract] [Full Text] [Related]
3. Utility of GLP-1R agonists in diabetes requires long term study.
de Oliveira JM
BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904
[No Abstract] [Full Text] [Related]
4. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
[TBL] [Abstract][Full Text] [Related]
6. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
Holst JJ; Seino Y
Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
[No Abstract] [Full Text] [Related]
8. Liraglutide in the treatment of obesity.
Ng SY; Wilding JP
Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists for type 2 diabetes.
De Block CE; Van Gaal LF
Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
[No Abstract] [Full Text] [Related]
12. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Sodhi M; Rezaeianzadeh R; Kezouh A; Etminan M
JAMA; 2023 Nov; 330(18):1795-1797. PubMed ID: 37796527
[TBL] [Abstract][Full Text] [Related]
13. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
14. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
16. Incretin hormones and the satiation signal.
Holst JJ
Int J Obes (Lond); 2013 Sep; 37(9):1161-8. PubMed ID: 23295502
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
18. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
19. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Hansen KB; Knop FK; Holst JJ; Vilsbøll T
Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
